Want to see AU:MX1 full AI Analyst Report?
MX1 Stock Chart & Stats
AU$0.10
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.10
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.12
Previous CloseN/A
Volume191.73K
Average Volume (3M)189.28K
Market Cap
AU$24.69M
Enterprise ValueAU$68.28
Total Cash (Recent Filing)AU$4.90M
Total Debt (Recent Filing)AU$5.13M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 27, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding748,032,960
10 Day Avg. Volume131,613
30 Day Avg. Volume189,275
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)3.96
Price to Sales (P/S)2.29
P/FCF Ratio-3.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.15Price Target Upside50.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$28.90M
Bulls Say, Bears Say
Bulls Say
Proprietary X‑ray TechnologyThe company’s carbon‑nanotube cold cathode X‑ray tube is a structural competitive advantage enabling truly compact, lightweight systems for field use. This IP supports product differentiation, higher margins on specialized units, and opportunities for licensing or component sales over the next several years.
High Gross MarginA sustained gross margin near 80% indicates durable product-level profitability and pricing power or low variable cost content. If fixed operating costs are controlled, this margin base allows the company to reach net profitability as sales scale, underpinning long‑term margin recovery potential.
Diversified End MarketsServing both medical mobile radiology and security/defence portable screening reduces single‑market dependence and provides multiple structural demand channels. Defence and healthcare procurement cycles are longer term, offering recurring service, replacement and upgrade opportunities that support durable revenue streams.
Bears Say
Declining Revenue And LossesA recent revenue decline and persistent negative profitability signal difficulty scaling commercial adoption and converting the high gross margin into operating profits. Continued top‑line weakness undermines reinvestment capacity and heightens execution risk over the medium term.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flows indicate the business is burning cash and likely dependent on external financing. This constrains the company’s ability to fund R&D, expand production, or support sales channels organically, increasing execution and funding risk into the next 2–6 months and beyond.
Rising Leverage And Weak ReturnsAn increased debt burden (D/E ~0.87) paired with negative ROE raises financial risk and limits flexibility to invest in growth or weather procurement timing in defence/medical markets. Higher leverage also increases interest obligations, which can exacerbate losses if revenue recovery is delayed.
Micro-X Ltd. News
MX1 FAQ
What was Micro-X Ltd.’s price range in the past 12 months?
Micro-X Ltd. lowest share price was AU$0.03 and its highest was AU$0.12 in the past 12 months.
What is Micro-X Ltd.’s market cap?
Micro-X Ltd.’s market cap is AU$24.69M.
When is Micro-X Ltd.’s upcoming earnings report date?
Micro-X Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 36 days.
How were Micro-X Ltd.’s earnings last quarter?
Micro-X Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of -AU$0.006 by -AU$0.004.
Is Micro-X Ltd. overvalued?
According to Wall Street analysts Micro-X Ltd.’s price is currently Undervalued.
Does Micro-X Ltd. pay dividends?
Micro-X Ltd. does not currently pay dividends.
What is Micro-X Ltd.’s EPS estimate?
Micro-X Ltd.’s EPS estimate is 0.
How many shares outstanding does Micro-X Ltd. have?
Micro-X Ltd. has 748,032,960 shares outstanding.
What happened to Micro-X Ltd.’s price movement after its last earnings report?
Micro-X Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of -AU$0.006. Following the earnings report the stock price went up 15.385%.
Which hedge fund is a major shareholder of Micro-X Ltd.?
Currently, no hedge funds are holding shares in AU:MX1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Micro-X Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.15 (50.00% Upside)
AU$0.15 (50.00% Upside)
Blogger Sentiment
Bullish
AU:MX1 Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$200.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.76%
Trailing 12-Months
Company Description
Micro-X Ltd.
Micro-X Limited designs, develops, manufactures, and commercializes imaging products for healthcare, defense, and security markets through cold cathode X-ray technology. The company provides carbon nanotube-based X-ray products, including core X-ray tube and high-voltage generator components. It also provides Rover Plus for medical performance in a mobile system; Head CT, a standard ambulance or retrieval aircraft for stroke; Checkpoints, a modular passenger self-screening checkpoint for airports; Baggage scanner, a CT baggage scanner for passenger self-screening checkpoints; Argus, a wide-area scattered projection backscatter and miniaturized high-voltage generator; and space imaging solutions. The company operates in Australia, the United States, the Asia-Pacific, Europe, the Middle East, and Africa. Micro-X Limited was incorporated in 2011 and is based in Tonsley, Australia.
MX1 Stock 12 Month Forecast
Average Price Target
AU$0.15
▲(50.00% Upside)
Technical Analysis
Compumedics Limited
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―







